What happens if I stop my GLP?

Understanding obesity as a chronic disease helps reduce stigma and shift expectations. Treatment is not about willpower—it is about biology. Long-term therapy is not a failure; it is appropriate chronic disease management.

Obesity is recognized as a chronic, relapsing disease. This indicates need for continued and life-long treatment. The natural history can include cycles of weight loss and weight gain.

After weight loss there are powerful biological adaptations that defend body weight and encourage weight regain. The body responds with hormonal and metabolic changes designed to restore it. Hunger hormones increase, satiety hormones decrease, resting metabolic rate may decline, and food cravings intensify. These adaptations can persist long after weight reduction, making maintenance extremely challenging without ongoing support. This speaks against previously held tenants about new "baseline" weights.

Modern anti-obesity medications (AOMs), particularly GLP-1 receptor agonists and GLP-1–based combination therapies, have transformed obesity care. Landmark trials including STEP trials (semaglutide) and the SURMOUNT trials (tirzepatide) have consistently shown substantial and sustained weight reduction during active treatment. These clinical trials, weight loss ranging range of 15–22% of total body weight. These levels are comparable to weight-loss with metabolic surgery. These therapies improve satiety, reduce hunger, slow gastric emptying, and influence reward pathways in the brain. There are additional downstream metabolic effects.

In one of the largest and most recent, systematic review and meta-analysis- of 37 trials including approx. 9,300 participants- found that stopping weight management medications (WMMs), including GLP-1 agonists, leads to rapid weight regain. This is consistent with other data found in the STEP trials and SURMOUNT trials. Participants regained weight at an average rate of 0.4 kg per month. That is about 1 pound per month. This can indicate complete weight regain in 1.5 years. Additionally the weight regain can reverse the cardiometabolic benefits of treatment like redeveloping hypertension and prediabetes/diabetes.

There are some strategy's that can help with maintenance. Like, share, and follow for more --